General
Preferred name
CINACALCET
Synonyms
CINACALCET HYDROCHLORIDE ()
AMG-073 hydrochloride ()
Cinacalcet HCl ()
AMG-073 HCl ()
AMG 073 (Cinacalcet) ()
Sensipar ()
Cinacalcet HCl ()
Cinacalcet (hydrochloride) ()
AMG 073 ()
AMG-073 (hydrochloride) ()
Cinacalcet (AMG-073) HCl ()
Mimpara, Sensipar,AMG-073 ()
AMG073, Sensipar, Cin ()
AMG073 ()
KRN-1493 ()
KRN1493 ()
AMG-073 ()
AMG073 HCL ()
AMG073 HYDROCHLORIDE ()
Mimpara ()
Cinacalcet (hydrochloride) ()
Cinacalcet-d3 (hydrochloride) ()
P&D ID
PD009594
CAS
364782-34-3
226256-56-0
1025064-29-2
2749807-20-1
Tags
natural product
drug
available
Approved by
EMA
FDA
First approval
2004
Drug Status
approved
withdrawn
Drug indication
Hyperparathyroidism
Kidney disease
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA
Cinacalcet directly lowers parathyroid hormone levels by increasing the sensitivity of the calcium sensing receptors to activation by extracellular calcium, resulting in the inhibition of PTH secretion. The reduction in PTH is associated with a concomitant decrease in serum calcium levels.
DESCRIPTION
Cinacalcet is a positive allosteric activator of the calcium-sensing receptor (CaSR), thus improving the effect of calcium on tissues expressing this receptor.
(GtoPdb)
DESCRIPTION
Cinacalcet is the first calcimimetic drug approved by the United States Food and Drug Administration for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
G protein-biased D2 partial agonist
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
34
BOC Sciences Bioactive Compounds
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
64
Molecular Weight
357.17
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
3
cLogP
6.14
TPSA
12.03
Fraction CSP3
0.27
Chiral centers
1.0
Largest ring
6.0
QED
0.52
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
calcium sensing receptor agonist
Agonist
Calcium-Sensing Receptor (CaSR) Agonists
calcium channel activator
Target
Calcium sensing receptor
CaSR
Endogenous Metabolite
Calcium Channel
Pathway
GPCR/G protein
Metabolic Enzyme/Protease
Primary Target
Calcium-Sensing Receptor
Member status
member
Indication
hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia
Disease Area
endocrinology, nephrology, oncology
ATC
H05BX01
Therapeutic Indication
Hyperparathyroidism
Therapeutic Class
Hormone Therapy
Calcimimetics
Source data
